Organization
Inmune Bio
5 clinical trials
Clinical trial
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Status: Recruiting, Estimated PCD: 2025-05-30
Clinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML)Status: Terminated, Estimated PCD: 2024-03-28
Clinical trial
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595Status: Recruiting, Estimated PCD: 2026-05-04
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of InflammationStatus: Withdrawn, Estimated PCD: 2023-10-26